About NOXXON
NOXXON’s oncology-focused pipeline acts on the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor micro-environment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 has delivered top-line data from a combination trial with the immuno-oncology checkpoint inhibitor, Keytruda®, in metastatic colorectal and pancreatic cancer patients in 2018.
|
|
Press ReleaseBerlin, Germany
2019, February 01 8:00 a.m. New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer 2019, January 14 6:00 p.m. Half-yearly report on the liquidity contract with Invest Securities 2019, January 04 8:00 a.m. Results of NOXXON's extra-ordinary general meeting of shareholders |
EventsAram Mangasarian Aram Mangasarian Aram Mangasarian, Jarl Ulf Jungnelius |